The aim of this work was to investigate the short- and long-term test-retest reliability of the 6-min walk distance (6MWD), peak heart rate, and nadir oxygen desaturation in idiopathic pulmonary fibrosis (IPF).
METHODS:
A reliability study of 70 adults with IPF was undertaken within out-patient pulmonary rehabilitation programs at 2 tertiary hospitals. Participants completed 2 baseline 6-min walk tests using a standard protocol, with continuous measures of percutaneous SpO2 and heart rate via pulse oximetry. The 6-min walk test was completed immediately following an intervention period and 6 months after. Reproducibility was assessed by intraclass correlation coefficient and Bland-Altman analysis.
RESULTS:
Participants with a mean ± SD diffusing capacity of the lung for carbon monoxide of 48 ± 14% were included. The reliability of the 6MWD was high (intraclass correlation coefficient = 0.96) with a mean learning effect of 21 m (95% CI 12–30 m). The learning effect persisted at 8 weeks (mean 14 m, 95% CI 5–23 m) but not 6 months (mean 15 m, 95% CI −1 to 30 m). Using the best (greatest) 6MWD significantly reduced the proportion of participants who were classified as having a clinically important response to rehabilitation compared with using the first 6MWD (40% vs 54%, P = .002). Nadir SpO2 was reproducible, with a mean difference of 0.7 ± 2.2%, and limits of agreement of −4 to 5%. Peak heart rate was more variable, with mean difference 5 ± 9 beats/min and limits of agreement of −12 to 20 beats/min.
CONCLUSIONS:
The 6MWD is a reproducible measure of exercise capacity in people with IPF. Whereas the nadir SpO2 may be accurately determined from one test, evaluating change in 6MWD with interventions may require 2 tests on each occasion. (ClinicalTrials.gov registration NCT0016828.)
RaghuG, CollardHR, EganJJ, MartinezFJ, BehrJ, BrownKK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011; 183(6):788–824.
2.
SwigrisJJ, GouldMK, WilsonSR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest, 2005; 127(1):284–294.
3.
NishiyamaO, TaniguchiH, KondohY, KimuraT, OgawaT, WatanabeF, NishimuraK. Health-related quality of life in patients with idiopathic pulmonary fibrosis: what is the main contributing factor?. Respir Med, 2005; 99(4):408–414.
4.
HollandAE, SpruitMA, TroostersT, PuhanMA, PepinV, SaeyD, et al. An official European Respiratory Society/American Thoracic Society Technical Standard: field walking tests in chronic respiratory disease. Eur Respir J, 2014; 44(6):1428–1446.
5.
du BoisRM, WeyckerD, AlberaC, BradfordWZ, CostabelU, KartashovA, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med, 2011; 183(9):1231–1237.
6.
HallstrandTS, BoitanoLJ, JohnsonWC, SpadaCA, HayesJG, RaghuG. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J, 2005; 25(1):96–103.
7.
CaminatiA, BianchiA, CassandroR, MirendaMR, HarariS. Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med, 2009; 103(1):117–123.
8.
LedererDJ, ArcasoySM, WiltJS, D'OvidioF, SonettJR, KawutSM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2006; 174(6):659–664.
9.
KingTEJr, BehrJ, BrownKK, du BoisRM, LancasterL, de AndradeJA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2008; 177(1):75–81.
10.
NoblePW, AlberaC, BradfordWZ, CostabelU, GlassbergMK, KardatzkeD, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet, 2011; 377(9779):1760–1769.
11.
HollandAE, HillCJ, ConronM, MunroP, McDonaldCF. Short term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax, 2008; 63(6):549–554.
12.
KozuR, JenkinsS, SenjyuH. Effect of disability level on response to pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology, 2011; 16(8):1196–1202.
13.
NishiyamaO, KondohY, KimuraT, KatoK, KataokaK, OgawaT, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology, 2008; 13(3):394–399.
14.
EatonT, YoungP, MilneD, WellsAU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med, 2005; 171(10):1150–1157.
15.
KozuR, JenkinsS, SenjyuH, MukaeH, SakamotoN, KohnoS. Peak power estimated from 6-minute walk distance in Asian patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease. Respirology, 2010; 15(4):706–713.
16.
HernandesNA, WoutersEF, MeijerK, AnnegarnJ, PittaF, SpruitMA. Reproducibility of 6-minute walking test in patients with COPD. Eur Respir J, 2011; 38(2):261–267.
17.
JenkinsS, CecinsNM. Six-minute walk test in pulmonary rehabilitation: do all patients need a practice test?. Respirology, 2010; 15(8):1192–1196.
18.
SpencerLM, AlisonJA, McKeoughZJ. Six-minute walk test as an outcome measure: are two six-minute walk tests necessary immediately after pulmonary rehabilitation and at three-month follow-up?. Am J Phys Med Rehabil, 2008; 87(3):224–228.
BrownAW, NathanSD. The value and application of the 6-minute-walk test in idiopathic pulmonary fibrosis. Ann Am Thorac Soc, 2018; 15(1):3–10.
21.
TomiokaH, ImanakaK, HashimotoK, IwasakiH. Health-related quality of life in patients with idiopathic pulmonary fibrosis–cross-sectional and longitudinal study. Intern Med, 2007; 46(18):1533–1542.
22.
CollardHR, KingTEJr, BartelsonBB, VourlekisJS, SchwarzMI, BrownKK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 2003; 168(5):538–542.
23.
FlahertyKR, AndreiAC, MurrayS, FraleyC, ColbyTV, TravisWD, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med, 2006; 174(7):803–809.
24.
HollandAE, HillCJ, GlaspoleI, GohN, DowmanL, McDonaldCF. Impaired chronotropic response to 6-min walk test and reduced survival in interstitial lung disease. Respir Med, 2013; 107(7):1066–1072.
25.
LettieriCJ, NathanSD, BrowningRF, BarnettSD, AhmadS, ShorrAF. The distance-saturation product predicts mortality in idiopathic pulmonary fibrosis. Respir Med, 2006; 100(10):1734–1741.
26.
LamaVN, FlahertyKR, ToewsGB, ColbyTV, TravisWD, LongQ, et al. Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med, 2003; 168(9):1084–1090.
27.
DowmanLM, McDonaldCF, HillCJ, LeeAL, BarkerK, GlaspoleI, et al. The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial. Thorax, 2017; 72(7):610–619.
28.
MillerMR, HankinsonJ, BrusascoV, BurgosF, CasaburiR, CoatesA, et al. Standardisation of spirometry. Eur Respir J, 2005; 26(2):319–338.
29.
MacintyreN, CrapoRO, ViegiG, JohnsonDC, van der GrintenCP, BrusascoV, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J, 2005; 26(4):720–735.
30.
KnudsonRJ, SlatinRC, LebowitzMD, BurrowsB. The maximal expiratory-flow volume curve: normal standards, variability and effects of age. Am Rev Respir Dis, 1976; 113(5):587–600.
31.
RocaJ, Rodriguez-RoisinR, CoboE, BurgosF, PerezJ, ClausenJL. Single-breath carbon monoide diffusing capacity prediction equations from a Mediterranean population. Am Rev Respir Dis, 1990; 141(4 Pt 1):1026–1032.
32.
FioreC, LeeA, McDonaldC, HillC, HollandA. Should oxyhaemoglobin saturation be monitored continuously during the 6-minute walk test?. Chron Respir Dis, 2011; 8(3):181–184.
33.
BorgG. Psycho physical bases of perceived exertion. Med Sci Sports Exerc, 1982; 14(5):377–381.
34.
PortneyLG, WatkinsMP. Foundations of clinical research: applications to practice. New Jersey: Prentice Hall; 2000:585–619.
35.
BlandJM, AltmanDG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet, 1986; 327(8476):307–310.
36.
JenkinsS, CecinsN, CamarriB, WilliamsC, ThompsonP, EastwoodP. Regression equations to predict 6-minute walk distance in middle-aged and elderly adults. Physiother Theory Pract, 2009; 25(7):516–522.
37.
EiserN, WillsherD, DoréCJ. Reliability, repeatability and sensitivity to change of externally and self-paced walking tests in COPD patients. Respir Med, 2003; 97(4):407–414.
38.
StevensD, ElpernE, SharmaK, SzidonP, AnkinM, KestenS. Comparison of hallway and treadmill six-minute walk tests. Am J Respir Crit Care Med, 1999; 160(5 Pt 1):1540–1543.
39.
HollandAE, DowmanL, FioreJJr, BrazzaleD, HillCJ, McDonaldCF. Cardiorespiratory responses to 6-minute walk test in interstitial lung disease: not always a submaximal test. BMC Pulm Med, 2014; 14:136.
40.
SwigrisJJ, SwickJ, WamboldtFS, SprungerD, du BoisR, FischerA, et al. Heart rate recovery after 6-min walk test predicts survival in patients with idiopathic pulmonary fibrosis. Chest, 2009; 136(3):841–848.
